These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7060315)

  • 1. Dose-response relationships for spironolactone at steady state.
    McInnes GT; Perkins RM; Shelton JR; Harrison IR
    Clin Pharmacol Ther; 1982 Mar; 31(3):317-23. PubMed ID: 7060315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone dose-response relationships in healthy subjects.
    McInnes GT; Perkins RM; Shelton JR; Harrison IR
    Br J Clin Pharmacol; 1982 Apr; 13(4):513-8. PubMed ID: 7066166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response relationships for spironolactone in combination with a potassium-wasting diuretic.
    McInnes GT; Clarke JM; Shelton JR
    Clin Pharmacol Ther; 1983 Jan; 33(1):35-43. PubMed ID: 6848297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.
    McInnes GT; Shelton JR; Harrison IR
    Clin Pharmacol Ther; 1981 May; 29(5):679-86. PubMed ID: 7214797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.
    McInnes GT; Shelton JR; Harrison IR; Perkins RM; Palmer RF
    Br J Clin Pharmacol; 1982 Feb; 13(2):187-94. PubMed ID: 7059416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L; Harrison I; Shelton J; Tidd M
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.
    Ramsay LE; Shelton JR; Tidd MJ
    Br J Clin Pharmacol; 1976 Jun; 3(3):475-82. PubMed ID: 788750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.
    Ramsay LE; Hessian P; Tidd MJ
    Br J Clin Pharmacol; 1975 Jun; 2(3):271-6. PubMed ID: 1234508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative potency of amiloride and spironolactone in healthy man.
    McInnes GT
    Clin Pharmacol Ther; 1982 Apr; 31(4):472-7. PubMed ID: 7060327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical potassium excretion in response to aldosterone antagonists.
    Ramsay LE; Harrison IR; Shelton JR; Tidd MJ
    Eur J Clin Pharmacol; 1977 Jan; 11(2):101-5. PubMed ID: 837961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid activity and the excretion of an oral potassium load in normal man.
    Hené RJ; Koomans HA; Rabelink AJ; Boer P; Dorhout Mees EJ
    Kidney Int; 1988 Nov; 34(5):697-703. PubMed ID: 3199680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 17. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia.
    McInnes GT; Harrison IR; Shelton JR; Perkins RM; Clarke JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):169-74. PubMed ID: 6487456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of spironolactone treatment on the renin-aldosterone system during pregnancy.
    Lammintausta R; Erkkola R
    Int J Clin Pharmacol Biopharm; 1979 Jul; 17(7):294-8. PubMed ID: 489194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone antagonism studies in the rhesus monkey.
    Hofmann LM; Pedrera HA; Suleymamov OD
    J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.
    Hensen J; Abraham WT; Dürr JA; Schrier RW
    Am J Nephrol; 1991; 11(6):441-6. PubMed ID: 1840232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.